| Code | CSB-RA801822MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to FPA-150, developed for research targeting VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1), also known as B7-H4 or B7S1. VTCN1 functions as an immune checkpoint protein that negatively regulates T cell-mediated immune responses by inhibiting T cell proliferation, cytokine production, and cytotoxic activity. This transmembrane glycoprotein is minimally expressed in normal tissues but becomes aberrantly overexpressed in numerous human cancers, including ovarian, lung, breast, pancreatic, and renal cell carcinomas, where it contributes to tumor immune evasion and correlates with poor prognosis and aggressive disease phenotypes.
FPA-150 represents a therapeutic antibody candidate designed to block VTCN1's immunosuppressive function, thereby enhancing anti-tumor immune responses. This biosimilar provides researchers with a valuable tool for investigating VTCN1-mediated immune regulation, exploring its role in tumor microenvironment modulation, and studying potential immunotherapeutic strategies for cancer treatment. The antibody enables mechanistic studies of immune checkpoint pathways and supports preclinical evaluation of VTCN1 as a therapeutic target in immuno-oncology research.
There are currently no reviews for this product.